IFX has been studied extensively in the IBD population and can effectively induce and maintain enteric mucosal healing.17 However, given its systemic mode of action, this drug is also associated with serious AEs such as infections and malignancy.18 It is important to recognize that the vast majority of studies of IFX provide data on the safety of the long-term TNF-ɑ blockade in a non-cancer population. The gene discussed is TNF; the disease is infection.